View in EDS

MIRASOL: A randomized, open-label, phase 3 study of mirvetuximab soravtansine vs. investigator's choice of chemotherapy in advanced high-grade epithelial ovarian, primary peritoneal, or fallopian tube cancers with high folate-alpha (FRα) expression (297)

Saved in:
Bibliographic Details
Title: MIRASOL: A randomized, open-label, phase 3 study of mirvetuximab soravtansine vs. investigator's choice of chemotherapy in advanced high-grade epithelial ovarian, primary peritoneal, or fallopian tube cancers with high folate-alpha (FRα) expression (297)
Authors: Moore, Kathleen1 (AUTHOR), Konecny, Gottfried2 (AUTHOR), Martin, Lainie3 (AUTHOR), Floquet, Anne4 (AUTHOR), O'Malley, David5 (AUTHOR), Colombo, Nicoletta6 (AUTHOR), Mantia-Smaldone, Gina7 (AUTHOR), Banerjee, Susana8 (AUTHOR), Gilbert, Lucy9 (AUTHOR), de Gregorio, Nikolaus10 (AUTHOR), Tromp, Jacqueline11 (AUTHOR), Wang, Jiuzhou12 (AUTHOR), Esteves, Brooke12 (AUTHOR), Method, Michael12 (AUTHOR), Van Gorp, Toon13 (AUTHOR)
Source: Gynecologic Oncology. 2022 Supplement 1, Vol. 166, pS156-S157. 2p.
Database: Academic Search Ultimate
Description
ISSN:00908258
DOI:10.1016/S0090-8258(22)01518-9